Overview

A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind study to compare the efficacy and safety of daily doses of Cenestin 0.3 mg tablets to placebo in reducing the frequency and severity of moderate to severe hot flashes in postmenopausal women.
Phase:
Phase 3
Details
Lead Sponsor:
Duramed Research
Treatments:
Estrogens
Estrogens, Conjugated (USP)
Estrogens, conjugated synthetic A